Protecting the blood supply. NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Protecting the blood supply.

Transfus Med Rev. 1989 Jan;3(1 Suppl 1):9-12. Unique Identifier : AIDSLINE MED/92223671
Bianco C; Greater New York Blood Center, New York 10021.

Abstract: Prevention of the transmission of the acquired immunodeficiency syndrome (AIDS) by transfusion has been the most successful area of epidemiologic control of the disease. Only 2% of the more than 50,000 cases reported to the Centers for Disease Control (CDC) have been attributed to transfusion, and the vast majority of these patients were infected before the introduction of screening tests in April 1985. The overall prevention program involves donor education, adequate medical history, physical examination, and mechanisms that allow exclusion of individuals at risk in a confidential manner. The current screening tests for human immunodeficiency virus (HIV) antibodies are highly sensitive, and the Western blot confirmatory test is highly specific. The present program can be used as a model in screening for other viruses and diseases, and its success has stimulated current work in developing multiple-retrovirus screening tests to detect either several retroviruses simultaneously or elements that are common to all retroviruses.
Keywords: Acquired Immunodeficiency Syndrome/*PREVENTION & CONTROL Blood Banks/*STANDARDS Blood Transfusion/*ADVERSE EFFECTS Counseling Human Mass Screening/*METHODS New York/EPIDEMIOLOGY Risk Factors JOURNAL ARTICLEKWDacquiredimmunodeficiencysyndrome/KWDprevention&controlbloodbanks/KWDstandardsbloodtransfusion/KWDadverseeffectscounselinghumanmassscreening/KWDmethodsnewyork/epidemiologyriskfactorsjournalarticle
920730
M9271088

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .